import
fieldwith
emerg
highli
pathogen
avian
influenza
virus
cross
speci
barrier
respons
lethal
infect
human
mani
countri
urgent
need
develop
effect
vaccin
produc
larg
quantiti
short
notic
confer
broad
protect
variant
order
meet
potenti
global
vaccin
demand
pandem
scenario
new
vaccineproduct
strategi
must
explor
addit
current
use
eggbas
technolog
season
influenza
attract
alternativesuppl
current
licens
eggbas
influenza
vaccin
adbas
vaccin
rel
inexpens
manufactur
product
process
requir
either
chicken
egg
labor
intens
timeconsum
process
necessit
enhanc
biosafeti
facil
importantli
pandem
situat
vaccin
strategi
could
offer
stockpil
option
reduc
respons
time
strainmatch
vaccin
could
develop
review
discuss
advector
technolog
current
progress
develop
adbas
influenza
vaccin
take
home
messagead
vectorbas
influenza
vaccin
pandem
prepared
develop
meet
global
vaccin
demand
keyword
adenovir
vector
influenza
vaccin
pandem
influenza
vaccin
vector
immun
highlight
adenoviru
ad
vectorbas
vaccin
manufactur
stockpil
larg
quantiti
short
notic
inexpens
cell
culturebas
technolog
without
need
enhanc
biosafeti
facil
ad
vectorbas
vaccin
induc
balanc
humor
cellmedi
immun
respons
due
activ
innat
immun
mani
strategi
hold
promis
circumvent
preexist
vector
immun
includ
use
nonhuman
ad
vector
heterolog
primeboost
approach
encapsul
ad
vector
algin
microspher
link
ad
vector
peg
use
immunosuppress
agent
coval
modif
viral
capsid
fiber
protein
order
prepar
potenti
influenza
pandem
new
influenza
vaccin
confer
broad
protect
multipl
strain
produc
time
manner
easili
stockpil
ad
vectorbas
influenza
vaccin
demonstr
consider
potenti
preclin
limit
clinic
studi
adenovirus
ad
nonenvelop
dna
virus
consist
linear
doublestrand
dna
genom
approxim
kilo
base
pair
kbp
sinc
initi
discoveri
fiftyon
differ
human
ad
serotyp
identifi
serotyp
extens
character
genet
biochem
number
ad
serotyp
avian
bovin
canin
ovin
porcin
nonhuman
primat
also
character
ad
shown
tremend
promis
deliveri
vehicl
recombin
vaccin
gene
therapi
attribut
make
ad
vector
suitabl
candid
gene
deliveri
applic
includ
safeti
rel
eas
vector
develop
ii
abil
infect
wide
rang
activ
divid
nondivid
mammalian
cell
induc
highlevel
transgen
express
iii
minimum
risk
integr
host
genom
iv
capac
grown
high
titer
tissu
cultur
v
avail
certifi
cell
line
technolog
larg
scale
purif
vi
inher
properti
serv
adjuv
activ
innat
immun
vii
develop
high
level
antigenspecif
humor
cellmedi
immun
respons
respons
vector
deliveri
either
via
system
mucos
rout
sinc
first
use
express
vector
ad
vector
receiv
tremend
attent
gene
deliveri
vehicl
vaccin
antigen
extens
test
vaccin
deliveri
system
sever
preclin
clinic
studi
number
infecti
diseas
includ
measl
hepatitisb
rabi
anthrax
ebola
sever
acut
respiratori
syndrom
sar
human
immunodefici
viru
malaria
tuberculosi
influenza
two
basic
type
ad
vector
util
gene
deliveri
applic
first
type
ad
vector
replicationcompet
ad
rca
vector
earli
region
genom
intact
transgen
express
cassett
typic
region
second
type
ad
vector
replicationdefect
typic
due
partial
complet
delet
region
transgen
express
cassett
insert
region
replicationdefect
ad
rda
vector
gain
tremend
popular
due
high
safeti
profil
typic
three
class
rda
vector
current
develop
vaccin
gene
therapi
purpos
ad
vector
delet
andor
term
earli
first
gener
ad
vector
vector
delet
region
reduc
toxic
vector
immun
denot
second
gener
ad
vector
third
gener
ad
vector
call
helperdepend
gutless
vector
nearli
viral
gene
replac
foreign
sequenc
leav
packag
signal
invert
termin
repeat
itr
intact
classif
appli
major
human
nonhuman
ad
vector
exclud
avian
ovin
vector
seem
earli
region
similar
numer
strategi
develop
construct
ad
vector
carri
foreign
gene
insert
tradit
ad
vector
construct
use
two
standard
method
first
method
vitro
ligat
method
involv
ligat
dna
fragment
obtain
restrict
digest
plasmid
carri
foreign
gene
insert
flank
ad
sequenc
dna
fragment
repres
rest
ad
genom
second
method
consist
homolog
recombin
permiss
cell
line
two
plasmid
shuttl
plasmid
carri
foreign
gene
insert
flank
ad
sequenc
sitespecif
insert
genom
plasmid
carri
almost
entir
ad
genom
classic
method
vector
construct
usual
low
effici
sometim
contamin
parent
viru
altern
approach
develop
circumv
limit
tradit
method
one
strategi
base
highli
effici
homolog
recombin
machineri
e
coli
gener
ad
vector
homolog
recombin
linear
intact
plasmid
contain
almost
entir
ad
genom
shuttl
plasmid
contain
exogen
express
cassett
flank
homolog
sequenc
site
insert
ad
genom
gener
infecti
clone
modif
andor
insert
desir
region
similar
strategi
employ
homolog
recombin
yeast
report
strategi
involv
homolog
recombin
ad
dna
yeast
artifici
chromosom
yac
vector
contain
sequenc
left
right
termini
ad
genom
result
gener
yeast
artifici
chromosom
contain
infecti
copi
ad
genom
transfect
excis
ad
genom
appropri
cell
result
gener
infecti
virion
order
overcom
low
effici
homolog
recombin
mammalian
cell
approach
base
bacteriophag
creloxp
recombin
system
develop
ad
vector
gener
result
cremedi
site
specif
recombin
two
plasmid
cotransfect
suitabl
cell
line
express
cre
recombinas
frequenc
vector
gener
use
creloxpbas
system
found
higher
compar
tradit
homolog
recombin
method
larg
scale
manufactur
clinic
grade
viral
vaccin
requir
effici
scalabl
product
purif
method
tradit
method
ad
vector
product
involv
vector
propag
anchoragedepend
packag
cell
line
small
cell
cultur
devic
roller
bottl
tflask
cell
factori
follow
purif
virus
cell
lysat
cesium
chlorid
cscl
densitygradi
centrifug
approach
suitabl
product
smallscal
vector
lot
approxim
viral
particl
vp
suffici
preclin
studi
scale
achiev
larg
quantiti
vp
clinic
grade
prepar
order
overcom
limit
associ
tradit
anchoragedepend
cultur
process
microcarri
bioreactor
system
suspens
cell
cultur
bioreactor
system
use
larg
scale
cultiv
variou
cell
line
support
growth
ad
vector
larg
scale
mammalian
cell
cultur
system
sever
advantag
includ
potenti
scaleup
eas
harvest
downstream
process
qualiti
assur
process
control
low
product
cost
microcarri
bioreactor
system
consist
cytodex
microcarri
success
use
larg
scale
cultiv
anchoragedepend
human
embryon
kidney
hek
cell
need
ad
vector
product
system
provid
high
surfacetovolum
ratio
result
high
cell
densiti
cell
per
millilit
produc
high
viral
titer
typic
total
ad
vector
yield
l
microcarri
bioreactor
vp
larg
scale
product
ad
vector
also
carri
larg
suspens
cultur
bioreactor
use
continu
cell
line
human
embryon
retin
cell
line
cell
adapt
grow
suspens
serumfre
media
serumfre
suspens
cultur
system
oppos
microcarri
cultur
system
rel
easi
oper
straightforward
scale
l
capac
two
type
suspens
bioreactor
use
larg
scale
product
ad
vector
wave
bioreactor
stir
tank
bioreactor
typic
viru
yield
use
suspens
cell
cultur
system
approxim
vpl
cultur
therefor
expect
yield
l
bioreactor
would
vp
experiment
purifi
viru
yield
approxim
vp
obtain
l
bioreactor
total
viru
cell
lysat
yield
equival
vaccin
dose
vp
per
inocul
use
larg
scale
purif
ad
vector
usual
carri
use
variou
chromatograph
techniqu
chromatograph
process
shown
great
scaleup
potenti
includ
affin
chromatographi
anionexchang
chromatographi
sizeexclus
chromatographi
membran
chromatographi
twostep
purif
strategi
involv
sequenti
chromatographi
chromatographytandem
ultracentrifugationfiltr
commonli
use
larg
scale
purif
ad
vector
two
step
process
consist
initi
chromatographi
step
captur
ad
nucleasetr
benzonasepulmozym
cell
lysat
second
step
use
polish
chromatographi
get
rid
cellular
virusfre
protein
chromatograph
techniqu
either
alon
combin
found
effici
larg
scale
purif
ad
vector
sinc
scalabl
input
viral
particl
per
run
chromatograph
strategi
current
use
ad
vector
purif
seem
minimum
advers
impact
viru
infect
yield
puriti
import
especi
pandem
scenario
larg
quantiti
highli
purifi
adbas
vaccin
would
requir
short
period
time
estim
entir
process
identif
vaccin
viru
vaccin
formul
fill
use
adenoviru
vectorbas
vaccin
technolog
approxim
week
schemat
diagram
adbas
influenza
vaccin
manufactur
process
shown
fig
due
inher
immunogen
ad
vector
known
activ
innat
adapt
immun
respons
system
administr
ad
vector
result
dosedepend
proinflammatori
respons
character
secret
proinflammatori
cytokin
chemokin
includ
tumor
necrosi
factoralpha
interleukin
il
interferongamma
induc
regul
activ
normal
express
secret
rant
monocyt
chemoattract
macrophag
inflammatori
protein
mip
alpha
innat
immun
respons
elicit
ad
vector
shown
mediat
tlrdepend
tlrindepend
pathway
ad
vectorinduc
matur
dendrit
cell
seem
inflammatori
respons
consider
reduc
efficaci
gene
transfer
caus
notic
morbid
transduc
host
high
vector
dose
proinflammatori
respons
also
influenc
develop
adspecif
cellular
humor
immun
respons
five
seven
day
post
viral
transduct
adspecif
ctl
gener
cellular
immun
respons
mediat
ctl
elimin
target
cell
express
viral
transgen
product
thu
limit
durat
transgen
express
cellular
immun
respons
ad
vector
overcom
use
newer
gener
ad
vector
diminish
adapt
immun
respons
highcapac
helperdepend
ad
vector
shown
greatli
attenu
adspecif
cellular
immun
respons
mediat
high
level
transgen
express
substanti
period
time
due
ubiquit
natur
human
ad
larg
percentag
human
popul
variabl
level
neutral
antibodi
know
preexist
vector
immun
vector
immun
one
serotyp
neutral
antibodi
direct
viral
capsid
compon
advers
affect
uptak
vector
target
cell
level
vector
immun
vari
base
age
sinc
children
young
adult
usual
higher
titer
compar
older
peopl
ad
neutral
antibodi
persist
year
pose
challeng
repeat
administr
necessari
approach
involv
prime
dna
vaccin
boost
adbas
vaccin
shown
promis
overcom
suppress
effect
antihad
immun
primeboost
strategi
advantag
induc
cellular
humor
immun
respons
current
evalu
preclin
clinic
studi
number
infecti
diseas
includ
ebola
viru
hepat
c
viru
anthrax
venezuelan
equin
enceph
viru
influenza
viru
oral
intranas
deliveri
hadbas
vaccin
also
shown
partial
overcomebypass
suppress
effect
immun
result
better
transgenespecif
immun
respons
howev
studi
need
rule
safeti
issu
relat
dissemin
intranas
administ
ad
vector
central
nervou
system
cn
via
olfactori
tissu
addit
encapsul
ad
vector
algin
microspher
link
vector
polyethylen
glycol
peg
use
immunosuppress
agent
cyclosporin
cyclophosphamid
coval
modif
viral
capsid
fiber
protein
use
ad
vector
deriv
nonhuman
ad
evalu
purpos
evad
preexist
vector
immun
clinic
util
vector
sever
hamper
due
high
preval
vector
immun
human
popul
import
preexist
vector
immun
inhibit
vectorbas
gene
deliveri
human
well
understood
howev
implic
modul
transgen
express
ad
vector
still
potenti
concern
order
overcom
limit
ad
vector
deriv
number
nonhuman
ad
speci
explor
nonhuman
ad
develop
deliveri
vehicl
vaccin
gene
therapi
includ
bovin
ad
porcin
ad
ovin
ad
fowl
ad
chimpanze
adenoviru
key
featur
make
nonhuman
ad
suitabl
vector
gene
deliveri
applic
nonpathogen
human
abil
transduc
wide
rang
human
nonhuman
cell
type
effici
express
foreign
gene
target
cell
well
character
genom
absenc
vector
crossneutr
antibodi
human
number
studi
nonhuman
ad
vector
anim
model
demonstr
vector
elud
high
level
immun
replicationincompet
vector
deriv
less
preval
serotyp
belong
subgroup
b
e
f
also
explor
suitabl
altern
vector
gene
therapi
vaccin
purpos
among
subgroup
b
serotyp
gain
attent
due
abil
infect
cell
use
membran
complement
protein
express
human
cell
attract
featur
vector
includ
expand
cell
tropism
low
seropreval
human
popul
abil
evad
preexist
immun
howev
level
adapt
immun
respons
induc
vector
especi
deriv
serotyp
shown
lower
compar
obtain
vector
low
immunogen
vaccin
attribut
car
coxsackievirusadenoviru
receptor
independ
tropism
fiber
modifi
vector
contain
fiber
knob
shown
immunogen
vector
thu
appear
ad
capsid
protein
influenc
develop
adapt
immun
respons
ad
vector
use
deliveri
vehicl
gene
therapi
vaccin
consid
nonpathogen
human
oral
deliveri
live
entericco
vaccin
protect
admedi
respiratori
diseas
success
use
us
militari
recruit
sinc
earli
without
advers
effect
suggest
safeti
aspect
adbas
vaccin
approxim
worldwid
clinic
trial
gene
therapi
infecti
diseas
util
ad
vector
sixti
cancer
gene
therapi
trial
use
vector
express
approv
treatment
sever
form
cancer
journal
gene
medicin
http
wwwwileycomlegacywileychigenmedclin
commerci
use
express
gendicin
oncolyt
ad
therapeut
intervent
varieti
tumor
state
food
drug
administr
sfda
china
promis
step
develop
ad
vector
human
use
ad
vector
also
exhibit
favor
safeti
profil
clinic
trial
vaccin
number
infecti
diseas
phase
clinic
studi
vaccin
demonstr
hadbas
vaccin
safe
well
toler
immunogen
howev
phase
ii
clinic
trial
hadvector
hiv
vaccin
failur
presum
presenc
preexist
antihad
antibodi
hivmedi
activ
cell
creat
favor
environ
hiv
replic
therefor
preliminari
screen
target
popul
vector
neutral
antibodi
would
essenti
prior
vaccin
least
phase
clinic
trial
conduct
evalu
safeti
immunogen
hadbas
influenza
vaccin
human
show
promis
result
intranas
epicutan
inocul
hadbas
influenza
vaccin
twentyfour
healthi
human
adult
volunt
result
mild
side
effect
subsid
within
hour
follow
inocul
number
phase
clinic
trial
current
progress
evalu
safeti
efficaci
adbas
vaccin
infecti
diseas
includ
malaria
ebola
viru
influenza
tuberculosi
http
wwwclinicaltrialsgov
http
wwwpaxvaxcom
howev
field
adbas
gene
therapi
setback
eighteenyearold
patient
jessi
gelsing
ornithin
transcarbamylas
otc
defici
die
follow
administr
ad
vector
particl
directli
hepat
arteri
death
attribut
system
adinduc
shock
syndrom
caus
cytokin
cascad
lead
dissemin
intravascular
coagul
acut
respiratori
distress
multiorgan
failur
suscept
damag
induc
high
amount
vector
particl
may
vari
individu
individu
sinc
femal
patient
receiv
similar
dose
ad
vector
trial
show
signific
side
effect
immun
vector
dose
sever
hundredfold
lower
dose
use
gene
therapi
trial
rout
immun
either
via
intramuscular
intranas
oral
intracutan
rather
intraven
safeti
ad
deliv
via
rout
either
vaccin
gene
therapi
purpos
extens
investig
satisfactori
result
despit
signific
advanc
scienc
technolog
influenza
remain
major
global
publichealth
problem
accord
world
health
organ
influenza
virus
infect
global
popul
annual
result
death
unit
state
alon
estim
influenza
infect
million
peopl
everi
year
result
hospit
death
make
seventh
lead
caus
death
annual
influenza
affect
peopl
age
group
highest
risk
complic
occur
among
children
age
two
year
peopl
year
older
pregnant
women
peopl
certain
medic
condit
cancer
chronic
lung
diseas
heart
diseas
diabet
blood
lung
kidney
disord
th
centuri
wit
three
major
influenza
pandem
spanish
flu
asian
flu
hong
kong
flu
pandem
account
million
death
worldwid
spanish
flu
sever
among
kill
peopl
unit
state
million
peopl
around
world
interestingli
peopl
die
spanish
flu
year
age
last
decad
human
infect
novel
subtyp
highli
pathogen
avian
influenza
hpai
report
first
case
human
infect
influenza
report
hpai
outbreak
poultri
farm
market
hong
kong
result
eighteen
case
six
death
sinc
viru
spread
mani
countri
asia
africa
europ
result
human
case
mortal
rate
addit
avian
influenza
subtyp
also
report
caus
human
infect
almost
four
decad
last
major
influenza
pandem
new
swinehumanavianorigin
influenza
viru
emerg
mexico
april
within
week
spread
around
world
result
first
influenza
pandem
st
centuri
pandem
lethal
fear
still
highlight
need
better
pandem
prepared
includ
effect
vaccin
vaccin
remain
effect
econom
way
prevent
influenza
infect
complic
two
type
influenza
vaccin
current
licens
use
human
inactiv
influenza
vaccin
wholesubvirion
live
attenu
influenza
vaccin
laiv
efficaci
vaccin
larg
depend
antigen
close
vaccin
viru
circul
strain
vaccin
viru
grown
embryon
chicken
egg
use
system
use
fifti
year
although
eggbas
system
wellestablish
product
season
influenza
vaccin
sever
limit
pandem
scenario
uncertainti
avail
billion
embryon
chicken
egg
enhanc
biosafeti
facil
produc
pandem
influenza
vaccin
pose
obviou
problem
sinc
vaccin
broadli
protect
stockpil
pandem
prepared
produc
larg
quantiti
short
notic
also
signific
concern
adapt
vaccin
viru
replic
egg
could
anoth
issu
henc
urgent
need
develop
eggindepend
influenza
vaccin
safe
protect
target
group
easi
manufactur
low
cost
highli
immunogen
thermost
protect
divers
influenza
strain
ad
vectorbas
influenza
vaccin
offer
sever
advantag
eggbas
influenza
vaccin
adbas
vaccin
inexpens
easier
manufactur
larg
quantiti
certifi
cell
line
short
notic
requir
enhanc
biosafeti
facil
replicationdefici
ad
vector
express
distinct
influenza
antigen
evalu
immunogen
protect
efficaci
varieti
anim
model
includ
mice
chicken
pig
well
clinic
trial
human
tabl
one
earliest
studi
immun
mice
ad
express
ha
gene
swine
influenza
viru
aswin
result
induct
high
level
antiinfluenza
neutral
hemagglutin
inhibit
hi
antibodi
titer
provid
partial
protect
lethal
challeng
heterolog
viru
phase
trial
involv
twentyfour
healthi
adult
volunt
intranas
epicutan
immun
replic
defect
ad
vector
encod
ha
gene
influenza
viru
result
fourfold
increas
hi
titer
particip
presenc
preexist
vector
immun
seem
signific
impact
result
haspecif
immun
respons
develop
replic
defect
result
demonstr
ad
vectorbas
vaccin
confer
crossprotect
antigen
distinct
strain
highli
pathogen
avian
influenza
virus
importantli
result
suggest
type
vaccin
strategi
offer
stockpil
option
pandem
situat
reduc
respons
time
strainmatch
vaccin
could
develop
similar
studi
anoth
group
ad
vectorbas
vaccin
advnha
express
ha
gene
use
immun
mice
chicken
mice
vaccin
intramuscularli
exhibit
high
level
neutral
antibodi
well
strong
haspecif
cellular
immun
respons
confer
protect
lethal
challeng
homolog
viru
chicken
immun
subcutan
advnha
vaccin
develop
high
hi
antibodi
titer
surviv
lethal
challeng
viru
dose
compar
given
mice
howev
intranas
vaccin
chicken
elicit
hi
antibodi
product
one
ten
chicken
confer
partial
protect
morbid
mortal
follow
homolog
viru
challeng
recent
studi
group
adbas
influenza
vaccin
encod
ha
gene
influenza
viru
found
effect
induc
protect
immun
lethal
challeng
homolog
influenza
viru
mice
determin
lowest
vaccin
dose
would
provid
protect
mice
anim
immun
intramuscularli
variou
amount
vaccin
vaccin
dose
low
plaqu
form
unit
pfu
abl
provid
protect
homolog
viru
challeng
even
though
level
hi
virusneutr
antibodi
titer
detect
limit
may
presum
due
altern
mechan
cmi
andor
nonneutr
nonhemagglutin
antibodi
higher
vaccin
dose
pfu
induc
humor
cellular
immun
respons
persist
least
twelv
month
postimmun
mice
challeng
ahong
viru
one
year
immun
fulli
protect
morbid
mortal
result
suggest
immun
respons
gener
adbas
influenza
vaccin
long
last
gener
influenza
viru
nucleoprotein
np
shown
elicit
immun
respons
essenti
viru
clearanc
follow
infect
sinc
np
rel
conserv
across
influenza
viru
subtyp
cellmedi
immun
cmi
respons
gener
usual
broad
crossprotect
order
broaden
vaccin
coverag
advector
vaccin
incorpor
ha
andor
np
gene
clade
clade
virus
gener
test
mice
intramuscular
immun
vaccin
result
gener
neutral
antibodi
virus
clade
addit
np
vaccin
broaden
vaccin
efficaci
differ
clade
significantli
higher
number
ha
np
specif
cell
observ
appar
could
crucial
impart
protect
antigen
distinct
virus
similar
multiantigen
approach
adbas
influenza
vaccin
gener
base
complex
recombin
ad
vector
cadvax
platform
ad
vector
devoid
region
incorpor
multipl
antigen
ha
avian
strain
spanish
influenza
strain
asouth
expect
protein
might
induc
broader
immun
protect
spectrum
hpai
strain
mice
vaccin
intraperiton
induct
strong
humor
cellular
immun
respons
pandem
influenza
viru
antigen
immun
anim
fulli
protect
challeng
strain
studi
highlight
multipleantigen
approach
broad
effici
protect
diverg
influenza
virus
dna
vaccin
incorpor
conserv
antigen
shown
confer
level
protect
divers
influenza
subtyp
howev
potenc
need
enhanc
one
approach
thatha
test
heterolog
primeboost
vaccin
recombinantvir
vector
use
boost
dna
vaccin
encod
thesam
antigen
mice
prime
dna
vaccin
boost
advector
vaccin
express
np
exhibit
stronger
cell
humor
respons
mice
immun
either
vaccin
alon
primeboost
regimen
provid
complet
protect
challeng
reassort
viru
strain
reassort
np
gene
partial
crossprotect
highli
pathogen
viru
strain
primeboost
approach
also
effect
significantli
reduc
viru
titer
lung
kidney
studi
highlight
import
dna
primead
boost
vaccin
strategi
enhanc
potenc
influenza
vaccin
influenza
viru
matrix
protein
highli
conserv
among
differ
influenza
viru
subtyp
henc
consid
potenti
vaccin
antigen
elicit
crossprotect
immun
multipl
influenza
viru
strain
mice
prime
vaccin
boost
adbas
vaccin
exhibit
broadli
crossreact
antibodi
cell
respons
confer
protect
challeng
homolog
heterolog
virus
subsequ
studi
group
dnaad
primeboost
approach
found
confer
better
protect
mice
challeng
highli
pathogen
viru
compar
coldadapt
ca
vaccin
mice
prime
boost
intramuscularli
dnaad
vaccin
encod
np
protein
develop
antigenspecif
humor
cellular
immun
respons
protect
challeng
highli
pathogen
viru
wherea
mice
vaccin
ca
vaccin
succumb
viru
challeng
although
immun
respons
gener
np
suffici
confer
protect
low
challeng
dose
hpai
good
enough
provid
complet
protect
higher
dose
hpai
viru
henc
vaccin
strategi
target
conserv
protein
need
incorpor
major
antigen
protein
ha
andor
na
enhanc
protect
efficaci
addit
fusion
conserv
viru
protein
molecular
adjuv
fmslike
tyrosin
kinas
ligand
granulocytemacrophag
colonystimul
factor
gmcsf
flagellin
defensin
codeliveri
cytokin
includ
could
boost
crossprotect
immun
respons
result
better
protect
incorpor
pathogenderiv
antigen
epitop
ad
capsid
protein
anoth
strategi
overcom
neg
impact
antiad
immun
observ
immun
respons
ad
capsid
protein
augment
repeat
ad
administr
therefor
immun
respons
epitop
incorpor
ad
capsid
protein
expect
augment
follow
repeat
administr
boost
ad
serotyp
ad
vector
express
ha
epitop
part
variou
capsid
protein
fiber
hexon
penton
protein
ix
gener
evalu
effici
induc
haspecif
immun
respons
despit
present
ha
epitop
lowest
copi
number
express
fiber
elicit
strongest
haspecif
immun
respons
compar
ha
epitop
incorpor
hexon
penton
protein
ix
indic
locat
antigen
epitop
ad
capsid
critic
factor
gener
epitopespecif
immun
respons
evalu
ad
vector
vaccin
vaccin
techniqu
chicken
massvaccin
larg
chicken
popul
respons
emerg
avian
influenza
pandem
feasibl
use
robot
ovo
injector
ovo
administr
ad
vector
vaccin
express
ha
viru
without
intranas
boost
result
potent
induct
humor
immun
ha
vaccin
chicken
fulli
protect
viru
partial
protect
hpai
viru
subsequ
studi
chicken
vaccin
ovo
advector
influenza
vaccin
contain
ha
gene
avian
influenza
strain
boost
intramuscularli
ad
vector
express
ha
achickennew
york
posthatch
develop
high
level
antibodi
ha
viru
strain
immun
chicken
complet
protect
challeng
hpai
viru
strain
show
signific
reduct
viru
shed
lung
adbas
influenza
vaccin
also
use
vaccin
pig
swine
influenza
virus
vaccin
pig
singl
dose
advector
vaccin
encod
ha
np
gene
swine
influenza
viru
result
significantli
high
level
virusspecif
hi
titer
confer
protect
challeng
close
relat
influenza
viru
obtain
farm
iowa
nasal
shed
viru
significantli
reduc
vaccin
pig
compar
nonvaccin
control
vaccin
also
found
suitabl
deliv
via
needlefre
pneumat
inject
devic
furthermor
sow
gilt
free
immun
had
advector
vaccin
efficaci
stimul
activ
immun
suckl
pig
even
presenc
interf
maternalderiv
antibodi
mention
studi
util
base
vaccin
variou
anim
model
howev
due
wide
preval
neutral
antibodi
human
popul
util
vector
could
advers
impact
numer
strategi
overcom
limit
propos
describ
earlier
review
one
promis
approach
overcom
limit
use
ad
vector
deriv
nonhuman
ad
serotyp
along
line
vaccin
base
chimpanze
bovin
ad
vector
investig
promis
result
chimpanze
advector
vaccin
np
encod
np
gene
influenza
viru
apuerto
sinai
use
immun
mice
intramuscular
vaccin
result
robust
antinp
tcell
respons
although
virusneutr
antibodi
detect
vaccin
mice
show
improv
surviv
rate
follow
challeng
homolog
viru
strain
well
heterolog
viru
strain
ahong
anoth
studi
bovin
advector
vaccin
express
ha
influenza
viru
ahong
abl
effici
elud
preexist
immun
mice
mimick
preexist
immun
vaccin
signific
reduct
induct
haspecif
hi
cmi
respons
observ
mice
compar
mice
furthermor
heterolog
primeboost
regimen
compris
prime
boost
elicit
significantli
higher
humor
immun
respons
compar
alon
mice
vaccin
show
complet
protect
morbid
mortal
follow
challeng
influenza
viru
ahong
result
strongli
suggest
import
nonhuman
adbas
influenza
vaccin
altern
hadvector
vaccin
also
heterolog
primeboost
strategi
combat
influenza
vaccin
consid
one
effect
way
prevent
control
infect
influenza
epidem
pandem
howev
high
incid
mutat
due
antigen
drift
antigen
shift
lifelong
immun
virus
singl
vaccin
possibl
henc
regular
updat
antigen
content
influenza
vaccin
essenti
remain
fulli
protect
season
influenza
viru
variant
new
pandem
influenza
virus
although
eggbas
technolog
effect
produc
enough
season
influenza
vaccin
everi
year
technolog
alon
may
abl
meet
global
demand
influenza
vaccin
pandem
situat
respons
limit
eggbas
vaccin
product
system
number
novel
vaccin
approach
fast
effici
costeffect
also
capabl
induc
intrasubtyp
crossprotect
explor
replac
supplement
current
technolog
advectorbas
influenza
vaccin
strategi
demonstr
consider
potenti
suitabl
altern
supplement
current
licens
eggbas
approach
meet
global
vaccin
demand
influenza
pandem
vaccin
approach
eggand
adjuvantindepend
use
approach
influenza
vaccin
produc
larg
quantiti
week
compar
tradit
egg
base
method
take
month
identif
pandem
strain
anoth
advantag
ad
base
approach
offer
flexibl
chang
antigen
content
vaccin
short
notic
adbas
vaccin
better
stabil
freezedri
state
tradit
eggbas
influenza
vaccin
almost
imposs
predict
even
ha
na
subtyp
next
pandem
influenza
viru
therefor
pandem
prepared
need
stockpil
prepandem
vaccin
cover
least
specif
subtyp
eg
could
use
strainmatch
vaccin
develop
accord
current
understand
immun
respons
protect
influenza
virus
prepandem
vaccin
ha
coupl
viru
strain
conserv
influenza
antigen
np
adbas
vaccin
technolog
seem
characterist
stockpil
prepandem
influenza
vaccin
given
limit
current
licens
eggbas
influenza
vaccin
manufactur
process
increas
global
demand
highli
effici
vaccin
manufactur
technolog
critic
strategi
serious
examin
increas
understand
conserv
b
andor
cell
epitop
influenza
virus
optimist
influenza
vaccin
could
provid
better
heterosubtyp
protect
would
avail
soon
influenza
virus
import
respiratori
pathogen
respons
widespread
infect
human
varieti
bird
pig
hors
marin
mammal
antigen
drift
accumul
point
mutat
viral
genom
creat
variant
escap
immun
previou
influenza
strain
caus
sever
epidem
everi
year
furthermor
genet
reassort
human
swine
avian
influenza
strain
lead
antigen
shift
result
viru
novel
ha
andor
na
major
human
popul
lack
immun
pandem
influenza
viru
origin
due
complex
recombin
event
involv
avian
human
swine
influenza
virus
hpai
virus
transmit
infect
poultri
human
lead
sever
infect
includ
death
sinc
diverg
distinct
clade
subclad
spread
mani
countri
asia
africa
europ
although
current
circul
virus
ineffici
persontoperson
spread
could
acquir
properti
emerg
avianhuman
reassort
coupl
mutat
ha
gene
segment
mention
event
renew
interest
develop
vaccin
strategi
capabl
induc
broad
crossreact
immun
novel
influenza
variant
anticip
global
spread
next
influenza
pandem
rapid
allow
littl
time
develop
product
tradit
strainmatch
vaccin
influenza
vaccin
induc
balanc
humor
cellmedi
immun
respons
confer
greater
degre
protect
antibodyescap
variant
season
pandem
influenza
virus
emerg
nonhuman
reservoir
adenoviru
ad
vectorbas
vaccin
repres
attract
alternativesuppl
current
licens
eggbas
influenza
vaccin
vaccin
advantag
induc
strong
humor
cellmedi
immun
respons
could
offer
protect
broad
spectrum
influenza
strain
sinc
adbas
vaccin
requir
use
live
influenza
virus
system
safe
conveni
econom
compar
tradit
influenza
virusbas
vaccin
approach
also
potenti
deliv
multipl
vaccin
antigen
singl
vector
broaden
protect
coverag
ad
vector
induc
strong
innat
immun
character
induct
proinflammatori
chemokin
cytokin
enhanc
develop
adapt
immun
respons
preferenti
target
antigenpres
cell
apc
facilit
antigen
present
fig
interact
apc
could
enhanc
express
apcbind
motif
ad
surfac
understand
ad
biolog
suggest
vaccin
system
need
explor
develop
vaccin
strategi
elderli
like
viral
vector
vaccin
common
concern
ad
vector
preval
variabl
level
ad
vector
immun
human
popul
preexist
ad
vector
immun
shown
decreas
immunogen
adbas
vaccin
anim
model
sever
strategi
overcom
limit
explor
shown
promis
preclin
studi
one
strategi
involv
use
vector
deriv
nonhuman
ad
studi
influenza
vaccin
found
overcom
except
high
level
preexist
immun
confer
complet
protect
challeng
homolog
lethal
viru
howev
preclin
clinic
studi
need
evalu
safeti
efficaci
nonhuman
ad
vector
heterolog
primeboost
regimen
involv
prime
dna
vaccin
boost
adbas
vaccin
prime
human
ad
vaccin
boost
nonhuman
adbas
vaccin
also
effect
overcom
limit
preexist
vector
immun
viru
characterist
time
next
influenza
pandem
difficult
predict
therefor
focu
pandem
prepared
stockpil
least
subtypespecif
prepandem
vaccin
time
period
strainmatch
vaccin
develop
anticip
identif
new
conserv
influenzaspecif
b
cell
epitop
would
certainli
help
develop
influenza
vaccin
could
provid
protect
number
divers
influenza
subtyp
overal
ad
vectorbas
influenza
vaccin
hold
great
promis
influenza
pandem
prepared
addit
prevent
season
influenza
issu
vector
immun
need
resolv
design
novel
ad
vector
seem
consider
clinic
evalu
adbas
influenza
vaccin
necessari
approv
human
applic
process
involv
identif
appropri
immunogen
need
incorpor
adenoviru
vector
exampl
hemagglutinin
ha
nucleoprotein
np
serv
excel
immunogen
influenza
virus
gene
interest
amplifi
rna
isol
influenza
viru
infect
cell
embryon
egg
revers
transcriptas
pcr
rtpcr
altern
codonoptim
gene
synthes
sequenc
known
gene
interest
control
appropri
promot
polyadenyl
site
requir
clone
shuttl
vector
order
gener
adenoviru
vector
carri
gene
interest
adenoviru
vector
character
express
appropri
immunogen
follow
prepar
viru
stock
certifi
cell
line
immunogen
vaccin
efficaci
test
appropri
anim
model
make
plan
larg
scale
vector
product
use
bioreactor
vector
viru
isol
bioreactor
process
viru
purif
concentr
follow
vaccin
formul
dispens
vaccin
readi
test
anim
speci
intend
adenoviru
vectorbas
vaccin
need
undergo
phase
iii
clinic
trial
could
distribut
human
use
